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experienced hands, the positive predictive value for mediastinal lymph 
node involvement is in the order of 85%, thus in the same range as for 
mediastinoscopy. Several studies have shown that these techniques 
have the potential to prevent surgical procedures to a large extent (up to 
70%) and are cost-effective as compared to surgical staging. Thus, the 
initial staging algorithm of the not-too-distant future could include a 
contrast CT of the chest and upper abdomen, a PET-CT, brain imag-
ing (as clinically indicated), and an E(B)US FNA. Such an algorithm 
would also allow for mediastinoscopy to be used more freely as a 
restaging tool after induction therapies for locally advanced NSCLC 
when surgical treatment is considered. The need for a tissue diagnosis 
in this situation is more pressing as the accuracy of CT and PET-CT 
after induction therapies, especially when radiotherapy is involved, is 
unknown and most probably lower as for initial staging. 
Response assessment
Response to chemo(radio) therapy could be a surrogate for survival 
in non-small cell lung cancer (NSCLC), but it has become a contro-
versial measurement parameter because of the quantitative variability 
in measurement and the fact that differences in response rates are not 
commonly translated into differences in survival. This is not surpris-
ing indeed, as treatment responses with commonly employed methods 
(i.e CT, MRI) are still being assessed by measuring tumor sizes before 
and after treatment and classifying tumor shrinkage according to 
criteria that were developed more than 25 years ago. Part of the current 
excitement about molecular imaging with PET lies in its more practical 
manifestations: to provide noninvasive evaluation of tumour metabolic 
status, location, and response to therapy. PET has been a key technol-
ogy for these applications because its sensitivity allows the use of 
labeled probes at concentrations that do not perturb tumour metabolism 
or saturate molecular signatures that are up-regulated on tumour cells 
as a result of oncogenic transformation. 18FDG PET has the potential to 
improve upon existing methods to predict outcome in NSCLC. First, it 
has been shown that 18FDG uptake (SUV) in untreated NSCLC is close-
ly correlated with survival. A recent study conﬁrmed that 18FDG SUV 
has independent prognostic value in a cohort of 100 subsequent surgi-
cal NSCLC patients. Also, reproducibility of 18FDG uptake in untreated 
NSCLC is high, in most studies <15%. Second, residual 18FDG uptake 
several months after completion of treatment of patients with (locally) 
advanced NSCLC has been shown to correlate with histopathological 
response and predict survival more accurate as compared to CT based 
methods. Third, in the recent years it has become clear that metabolic 
response early in the course of treatment, i.e. after 1 cycle of chemo-
therapy, allows for prediction of subsequent reduction in tumor mass as 
well as patient survival . The latter may allow for early identiﬁcation of 
non responders which is of great clinical importance since the response 
rates of chemotherapy in advanced NSCLC are usually in the range of 
25%-35%. 
However, several questions remain. The best method and optimal 
timing to measure 18FDG response in NSCLC is not known and there 
is no general agreement what decrease in 18FDG uptake constitutes a 
metabolic response. This may especially of relevance when assessing 
the newer molecular therapies where a metabolic effect on non-cancer 
tissue cannot be excluded. Finally, as a tracer of metabolism, 18FDG is 
not a speciﬁc tumor marker. Other tracers, eg. 18FLT that reﬂect other 
tumor characteristics (proliferation), are explored with respect to their 
suitability to assess response to anticancer treatment. 
To date, there are no clinical studies available in the literature that 
compare standard therapy with “PET-controlled” therapy. Patients in 
the PET-controlled arm would receive 1 cycle of standard therapy after 
which metabolic non-responders would switch to alternative treatment, 
whereas metabolic responders would continue standard treatment. End-
points in such trials would be cost of treatment, treatment related toxic-
ity and survival . Randomised trials of this design are eagerly awaited.
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Although reports of pulmonary malignancies date to antiquity, lung 
cancer is largely a disease of modern man (1, 2). Prior to 1900, lung 
cancers were viewed as “matters of medical curiosity not known to 
be in any degree inﬂuenced by medicine and too rare to be of much 
practical importance” (2). By the mid-20th century, however, lung 
cancer had become epidemic and ﬁrmly established as a leading cause 
of cancer-related death throughout much of the industrialized and de-
veloping world (3). For much of the 20th century the systemic treatment 
of advanced NSCLC was considered completely inadequate (4, 5). In 
fact, as recently as 1998 the noted oncologist B.J. Kennedy derisively 
commented on the “snail’s pace” of progress in the management of late 
stage NSCLC (6). Fortunately, much has changed since Dr. Kennedy’s 
scholarly rebuke. It is now well established that modern chemotherapy 
can prolong survival of NSCLC patients with late stage disease as well 
as improve the symptoms and quality of life in a cost effective manner 
(5, 7, 8). Although no single chemotherapy regimen stands apart as 
optimal treatment for all patients with advanced NSCLC, most experts 
agree that doublet platinum-based chemotherapy with a 3rd generation 
drug is the preferred treatment for physically ﬁt patients (7-9). Contro-
versy persists vis-à-vis the superiority of cisplatin versus carboplatin in 
the ﬁrst-line setting (10). Nonetheless, non-platinum therapy is a rea-
sonable alternative approach in selected circumstances where cisplatin 
or carboplatin is not appropriate. Subtle differences among the extant 
regimens allow clinicians ﬂexibility to choose among toxicity pro-
ﬁles, convenience, and cost (11, 12). For a subset of NSCLC patients, 
namely those with adenocarcinoma, no CNS metastases or hemoptysis, 
the addition of bevacizumab to chemotherapy is warranted based on a 
signiﬁcant improvement in overall survival (13). Whether the addition 
of bevacizumab to chemotherapy doublets other than carboplatin and 
paclitaxel proves beneﬁcial remains to be determined although initial 
reports are encouraging in this regard (14). The available data indicate 
that no more than three to six cycles of chemotherapy are required to 
achieve optimal survival results and minimize host toxicity (15, 16). 
Second line chemotherapy is clearly beneﬁcial in terms of survival, 
quality of life and cost (17). The choice of 2nd-line therapy is dictated 
largely by the toxicity proﬁles of the available drugs (18). Older pa-
tients who are physically ﬁt should be treated in a manner that mirrors 
that of their younger counterparts (19, 20). Older patients who are not 
physically ﬁt and patients with a poor initial performance status may 
be candidates for monotherapy with a 3rd generation cytotoxic drug 
or possibly one of the newer so-called targeted agents (e.g. erlotinib) 
(21). On a precautionary note, however, at least one small trial suggests 
chemotherapy may be superior to selected targeted agents in this setting 
(22). By contrast, EGFR tyrosine kinase inhibitors appear active as 
initial therapy for patients over the age of 70 years (23). A prospective 
comparative trial with chemotherapy is warranted. Physicians may one 
day employ biomarkers to select appropriate therapy for individual 
patients. Recent advances in molecular biology and proteomic research 
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suggest this intriguing approach may be a reality in the near future (24-
26). Finally, all therapy in the setting of metastatic disease is ultimately 
palliative. Consequently treatment decisions should be tempered by this 
sobering reality. 
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Recent years have witnessed improvements in the non-invasive staging 
of NSCLC and image-guided radiotherapy delivery, and it has seen an 
increased use of concurrent chemo-radiotherapy (CT-RT) for locally 
advanced NSCLC. This review will highlight clinical developments in 
3 key areas of NSCLC. 
Stage III NSCLC 
Two randomized trials have shown that the addition of surgery does 
not improve survival in comparison to either sequential CT-RT [1] or 
concurrent CT-RT alone [2]. A meta-analysis concluded that concurrent 
administration of concurrent CT-RT improved survival when compared 
to sequential CT-RT, but at the expense of increased acute esophagitis 
[3]. Despite an increased risk of hospitalizations, concurrent RT-CT is 
not a more costly treatment strategy [4]. Stage III NSCLC consists of a 
number of different subgroups of varying prognosis, and it is reason-
able to expect that further progress will come about in tailoring strate-
gies for subgroups that vary in risk for local recurrence and distant 
metastases. In patients at high risk for toxicity with concurrent CT-RT, 
use of sequential chemotherapy followed by accelerated radiotherapy 
schemes appears to result in favourable outcomes [5-6]. Clinically 
important subgroups include the following: 
i. Extent of nodal disease: Increase in the number of sites of nodal 
disease is associated with decreased survival [7]. For CT-RT in 
NSCLC, at least two major prognostic subgroups can be distin-
guished. The ﬁrst includes patients with small volume and/or single-
station N2 disease (ëoperable diseaseí). Patients included in trials of 
only CT-RT have tended to be characterised by metastases in two or 
more nodal stations and/or bulky nodes exceeding 3 cm. A median 
survival of 22.2 months has been reported for the former [2], while 
the best median survivals reported in randomised trials for the latter 
range from 17 to 17.5 months [8-9]. 
ii. Risk of treatment-related toxicity: The volume of normal lung 
treated to 20 Gy or more (V20) correlates with the risk for high-
grade pulmonary toxicity with CT-RT. A recent study revealed a 
poorer survival in patients with V20 values of ≥35% [10]. Clinical 
presentations that predict for high V20 values include metastases in 
the contralateral hilus and peripheral lower lobe tumors with contra-
lateral upper mediastinal nodes. The risk of high-grade esophagitis 
correlates with the volume of organ irradiated to high doses and the 
number of involved nodal stations [11].
Modern image-guided radiotherapy is now becoming available at major 
centers worldwide but the major clinical trials published in the last 2 
years mainly used 2-dimensional radiotherapy planning and elective 
nodal irradiation. Involved-ﬁeld radiotherapy is now the standard of 
care in stage III NSCLC as it results in both a lower incidence of pneu-
monitis and improves survival [12]. CT-based treatment planning is 
